Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 5 Results

Title
Intervention Indication Therapeutic Area Year Actions
Axicabtagene ciloleucel for relapsed/refractory indolent non-Hodgkin lymphoma Axicabtagene Ciloleucel (Yescarta; KTE-C19) Non-Hodgkin lymphoma (NHL) Haematological Cancer and Lymphomas 2019 View  |  Download
Lisocabtagene maraleucel for relapsed or refractory, aggressive B-cell non-Hodgkin Lymphoma – second line Lisocabtagene maraleucel (Liso-cel; JCAR017) Non-Hodgkin lymphoma (NHL) Haematological Cancer and Lymphomas 2020 View  |  Download
Lisocabtagene maraleucel for transplant-eligible and ineligible, relapsed or refractory, aggressive B-cell non-Hodgkin lymphoma - second-line Lisocabtagene maraleucel (Liso-cel; JCAR017) Diffuse large B-cell lymphoma (DLBCL) , Follicular lymphoma , Non-Hodgkin lymphoma (NHL) , Primary mediastinal large B-cell lymphoma (PMBCL) Haematological Cancer and Lymphomas 2020 View  |  Download
Phelinun for reduced intensity conditioning treatment prior to allogeneic haematopoietic stem cell transplantation Melphalan hydrochloride (Cydex; CDX-353; Phelinun) Acute myeloid leukaemia (AML) , Hodgkin lymphoma , Multiple myeloma (MM) , Neuroblastoma , Non-Hodgkin lymphoma (NHL) , Ovarian cancer Female Reproductive Cancer , Haematological Cancer and Lymphomas , Neurological Cancer 2021 View  |  Download
Zanubrutinib for Waldenstrom's Macroglobulinemia Zanubrutinib (BGB-3111; Brukinsa) Non-Hodgkin lymphoma (NHL) Haematological Cancer and Lymphomas 2018 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications